GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Genetic Analysis AS (XSAT:GEAN.TO.2) » Definitions » Capex-to-Revenue

Genetic Analysis AS (XSAT:GEAN.TO.2) Capex-to-Revenue : 0.00 (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Genetic Analysis AS Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Genetic Analysis AS's Capital Expenditure for the three months ended in Dec. 2023 was kr0.00 Mil. Its Revenue for the three months ended in Dec. 2023 was kr3.80 Mil.

Hence, Genetic Analysis AS's Capex-to-Revenue for the three months ended in Dec. 2023 was 0.00.


Genetic Analysis AS Capex-to-Revenue Historical Data

The historical data trend for Genetic Analysis AS's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genetic Analysis AS Capex-to-Revenue Chart

Genetic Analysis AS Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Revenue
1.13 0.90 0.29 0.02 0.05

Genetic Analysis AS Quarterly Data
Dec19 Jun20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.04 0.14 - -

Competitive Comparison of Genetic Analysis AS's Capex-to-Revenue

For the Diagnostics & Research subindustry, Genetic Analysis AS's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genetic Analysis AS's Capex-to-Revenue Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Genetic Analysis AS's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Genetic Analysis AS's Capex-to-Revenue falls into.



Genetic Analysis AS Capex-to-Revenue Calculation

Genetic Analysis AS's Capex-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-0.643) / 14.147
=0.05

Genetic Analysis AS's Capex-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (0) / 3.799
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Genetic Analysis AS  (XSAT:GEAN.TO.2) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


Genetic Analysis AS Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Genetic Analysis AS's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Genetic Analysis AS (XSAT:GEAN.TO.2) Business Description

Traded in Other Exchanges
Address
Kabelgata 8, Oslo, NOR, 0580
Genetic Analysis AS is a research-driven diagnostic company dedicated to delivering innovative diagnostic solutions to the growing human microbiota market. It is providing a CE-marked gut microbiota analysis for testing bacterial imbalance in IBS and IBD patients.

Genetic Analysis AS (XSAT:GEAN.TO.2) Headlines

No Headlines